Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy

European Journal of Endocrinology

Volumn 161, Issue 5, 2009, Pages 671-679

  Holmer, Helene ^a,b   Ekman, Bertil ^c   Björk, Jonas ^b   Nordstöm, Carl Henrik ^b   Popovic, Vera ^d   Siversson, AnnBritt ^b   Erfurth, Eva Marie ^b  

^a CENTRAL HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d University Clinical Center   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; CORTISONE; ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; INSULIN; LEPTIN; LEVOTHYROXINE; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE; PRASTERONE; SOMATOMEDIN C; TESTOSTERONE; THYROID HORMONE; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL; UNINDEXED DRUG; VASOPRESSIN; YTTRIUM; HUMAN GROWTH HORMONE;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; BRAIN VENTRICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CRANIOPHARYNGIOMA; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; NEUROSURGERY; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; PUBERTY; RISK ASSESSMENT; SWEDEN; TREATMENT DURATION; TUMOR GROWTH; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; DRUG EFFECT; HYPOPHYSIS TUMOR; HYPOTHALAMUS; METHODOLOGY; MIDDLE AGED; ONSET AGE; PATHOLOGY;

ADOLESCENT; ADULT; AGE OF ONSET; BODY COMPOSITION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CRANIOPHARYNGIOMA; CROSS-SECTIONAL STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOTHALAMUS; INSULIN; LEPTIN; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; YOUNG ADULT;

EID: 70449717048     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0449     Document Type: Article

References (41)

1. Bülow B, Attewell R, Hagmar L, Malmstrom P, Nordstrom CH & Erfurth EM. Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumour recurrence. Journal of Clinical Endocrinology and Metabolism 1998 11 3897-3904. (Pubitemid 28513569)
2. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC & Stewart PM. Association between premature mortality and hypopituitarism. Lancet 2001 357 425-431.
3. Pereira AM, Schmid EM, Schutte PJ, Voormolen JH, Biermasz NR, van Thiel SW, Corssmit EP, Smit JW, Roelfsema F & Romijn JA. High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clinical Endocrinology 2005 62 197-204. (Pubitemid 40203915)
4. De Vile CJ, Grant DB, Hayward RD & Stanhope R. Growth and endocrine sequelae of craniopharyngioma. Archives of Disease in Childhood 1996 75 108-114.
5. Karavitaki N, Cudlip S, Adams CB & Wass JA. Craniopharyngiomas. Endocrine Reviews 2006 27 371-397.
6. Müller HL, Emser A, Faldum A, Bruhnken G, Etavard-Gorris N, Gebhardt U, Oeverink R, Kolb R & Sorensen N. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. Journal of Clinical Endocrinology and Metabolism 2004 89 3298-3305. (Pubitemid 38951896)
7. Bray GA, Inoue S & Nishzawa Y. Hypothalamic obesity. The autonomic hypothesis and the lateral hypothalamus. Diabetologia 1981 20 366-377.
8. King BM. The rise, fall and resurrection of the ventromedial hypothalamus in the regulation of feeding behaviour and body weight. Physiology and Behavior 2006 87 221-244.
9. Lustig RH. Autonomic dysfunction of the beta-cell and the pathogenesis of obesity. Reviews in Endocrine and Metabolic Disorders 2003 4 23-32.
10. Roth C, Wilken B, Hanefels F, Schröter W & Leonhardt U. Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite. European Journal of Endocrinology 1998 138 89-91. (Pubitemid 28078816)
11. Harz KJ, Müller HL, Waldeck E, Pudel V & Roth C. Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. Journal of Clinical Endocrinology and Metabolism 2003 88 5227-5231. (Pubitemid 37452720)
12. Srinivasan S, Ogle GD, Garnett SP, Briody JN, Lee JW & Cowell CT. Features of the metabolic syndrome after childhood craniopharyngioma. Journal of Clinical Endocrinology and Metabolism 2004 89 81-86. (Pubitemid 38183863)
13. Geffner M, Lundberg M, Koltowska-Häggström M, Abs R, Verhelst J, Erfurth EM, Kendall-Taylor P, Price DA, Jonsson P & Bakker B. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer international growth database). Journal of Clinical Endocrinology and Metabolism 2004 89 5435-5440. (Pubitemid 39518422)
14. Link K, Moëll C, Garwicz S, Cavallin-Ståhl E, Björk J, Thilén U, Ahrén B & Erfurth EM. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukaemia in childhood. Journal of Clinical Endocrinology and Metabolism 2004 89 5005-5012. (Pubitemid 39391441)
15. Janssen I, Heymsfield SB, Baumgartner RN & Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. Journal of Applied Physiology 2000 89 465-471. (Pubitemid 30637091)
16. Alberti KG, Zimmet P & Shaw J. Metabolic syndrome - a newworldwide definition. A Consensus Statement from the International Diabetes Federation. Diabetic Medicine 2006 23 469-480.
17. de Ferranti SD & Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovascular Pathology 2007 16 14-21. (Pubitemid 46049026)
18. Rifai N & Ridker PM. Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clinical Chemistry 2003 49 666-669. (Pubitemid 36379538)
19. Walldius G & Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. Journal of Internal Medicine 2006 259 493-519.
20. Wilhelmsen L, Tibblin G, Aurell M, Bjure J, Ekström-Jodal B & Grimby G. Physical activity, physical fitness and risk of myocardial infarction. Advanced Cardiology 1976 18 217-230.
21. Tudor-Locke C, Burkett L, Reis JP, Ainsworth BE, Macera CA & Wilson DK. How many days of pedometer monitoring predict weekly physical activity in adults? Preventive Medicine 2005 40 293-298.
22. Fernandez-Real JM & Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews 2003 24 278-301. (Pubitemid 36724371)
23. Bray GA & Gallagher TF. Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. Medicine 1975 54 301-330.
24. Lustig RH. Childhood obesity: behavioural aberration or biochemical drive? Reinterpreting the first law of thermodynamics Nature Clinical Practice. Endocrinology and Metabolism 2006 2 447-458.
25. Müller HL, Handwerker G, Gebhardt U, Faldum A, Emser A, Kolb R & Sörensen N. Melatonin treatment in obese patients with childhood craniopharyngioma and increased daytime sleepiness. Cancer Causes and Control 2006 17 583-589.
26. Roth CL, Hunneman DH, Gebhardt U, Stoffel-Wagner B, Reinehr T & Müller HL. Reduced sympathetic metabolites in urine of obese patients with craniopharyngioma. Pediatric Research 2007 61 496-501. (Pubitemid 46569307)
27. Shulman GH, Rothman DL, Jue T, Stein P, DeFronzo RA & Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. New England Journal of Medicine 1990 322 223-228. (Pubitemid 20034509)
28. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F & Bruner JM. The descriptive epidemiology of craniopharyngioma. Journal of Neurosurgery 1998 89 547-551.
29. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM & Tauber M, European Society of Paediatric Endocrinology. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. European Journal of Endocrinology 2005 152 165-170.
30. Attanasio AF, Shavrikova E, Blum WF, Cromer M, Child CJ, Paskova M, Lebl J, Chipman JJ & Shalet SM. Hypopituitary Developmental Outcome Study Group. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 2004 89 4857-4862.
31. Johannsson G, Albertsson-Wikland K & Bengtsson BA. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. Journal of Clinical Endocrinology and Metabolism 1999 84 4516-4524.
32. Colao A, Di Somma C, Salerno M, Spinelli L, Orio F & Lombardi G. The cardiovascular risk of GH-deficient adolescents. Journal of Clinical Endocrinology and Metabolism 2002 87 3650-3655.
33. Verhelst J, Kendall-Taylor P, Erfurth EM, Price AD, Geffner M, Koltowska-Häggström M, Jonsson PJ, Wilton P & Abs R. Baseline characteristics and response to 2 years of growth hormone replacement of hypopituitary patients with growth hormone deficiency due to adult-onset craniopharyngioma in comparison to patients with non-functioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database). Journal of Clinical Endocrinology and Metabolism 2005 90 4636-4643. (Pubitemid 41166526)
34. Mah PM, Webster J, Jönsson P, Feldt-Rasmussen U, Koltowska-Häggström M & Ross RJ. Estrogen replacement in women of fertile years with hypopituitarism. Journal of Clinical Endocrinology and Metabolism 2005 90 5964-5969. (Pubitemid 41606512)
35. Sherif K. Benefits and risks of oral contraceptives. American Journal of Obstetrics and Gynecology 1999 180 343-348.
36. Lasco A, Frisina N, Morabito N, Gaudio A, Morini E, Trifiletti A, Basile G, Nicita-Mauro V & Cucinotta D. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology 2001 145 457-461. (Pubitemid 32927074)
37. Arlt W. Androgen therapy in women. European Journal of Endocrinology 2006 154 1-11.
38. Giavoli C, Libe R, Cobetta S, Ferrante E, Lania A, Arosio M, Spada A & Beck-Peccoz P. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 2004 89 5397-5401. (Pubitemid 39518415)
39. Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK & Ghigo E. Hypopituitarism. Lancet 2007 369 1461-1470.
40. Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, Tucker GT & Ross RJ. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clinical Endocrinology 2004 61 367-375. (Pubitemid 39287067)
41. Cappola AR & Ladenson PW. Hypothyroidism and atherosclerosis. Journal of Clinical Endocrinology and Metabolism 2003 88 2438-2444.